Adalta Capital Management’s Biogen BIIB Stock Holding History

Adalta Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$141K	–	89
2021 Q3	$141K	Hold	500	–	–	0.08%	83
2021 Q2	$173K	Sell	500 -300	-38%	-$90.9K	0.09%	81
2021 Q1	$224K	Hold	800	–	–	0.13%	70
2020 Q4	$196K	Hold	800	–	–	0.12%	69
2020 Q3	$227K	Hold	800	–	–	0.17%	62
2020 Q2	$214K	Hold	800	–	–	0.17%	56
2020 Q1	$253K	Hold	800	–	–	0.23%	52
2019 Q4	$237K	Buy	+800	New	+$222K	0.15%	62
2019 Q2	–	Sell	-800	Closed	-$189K	–	85
2019 Q1	$189K	Hold	800	–	–	0.14%	68
2018 Q4	$241K	Hold	800	–	–	0.23%	62
2018 Q3	$283K	Hold	800	–	–	0.2%	69
2018 Q2	$232K	Hold	800	–	–	0.16%	71
2018 Q1	$219K	Hold	800	–	–	0.17%	69
2017 Q4	$255K	Hold	800	–	–	0.19%	66
2017 Q3	$250K	Hold	800	–	–	0.2%	65
2017 Q2	$217K	Hold	800	–	–	0.18%	71
2017 Q1	$219K	Buy	+800	New	+$226K	0.19%	68

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adalta Capital Management's BIIB Position: Q4 2021 in Review

Adalta Capital Management sold out of Biogen (BIIB) in Q4 2021, closing a stake of 500 shares — an estimated $141K sold.

Adalta Capital Management first reported a position in BIIB in Q1 2017 and held it in 17 quarters. The position peaked at $283K in Q3 2018. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Adalta Capital Management reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Adalta Capital Management sold 500 Biogen shares in Q4 2021, an estimated $141K.
Adalta Capital Management first reported a position in Biogen in Q1 2017 and held it in 17 quarters.
Adalta Capital Management's Biogen position peaked at $283K in Q3 2018.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Adalta Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.